PE20090223A1 - Compuestos triciclicos como inhibidores de metaloproteinasas matriciales - Google Patents
Compuestos triciclicos como inhibidores de metaloproteinasas matricialesInfo
- Publication number
- PE20090223A1 PE20090223A1 PE2008000773A PE2008000773A PE20090223A1 PE 20090223 A1 PE20090223 A1 PE 20090223A1 PE 2008000773 A PE2008000773 A PE 2008000773A PE 2008000773 A PE2008000773 A PE 2008000773A PE 20090223 A1 PE20090223 A1 PE 20090223A1
- Authority
- PE
- Peru
- Prior art keywords
- sulfonamide
- dibenzo
- metaloproteinases
- matricial
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 abstract 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 abstract 2
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 abstract 2
- XNTWONAICPPJDM-UHFFFAOYSA-N furan-3-sulfonamide Chemical compound NS(=O)(=O)C=1C=COC=1 XNTWONAICPPJDM-UHFFFAOYSA-N 0.000 abstract 2
- -1 CARBOXYL Chemical class 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 abstract 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/76—Dibenzothiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92756307P | 2007-05-04 | 2007-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090223A1 true PE20090223A1 (es) | 2009-03-08 |
Family
ID=39944224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008000773A PE20090223A1 (es) | 2007-05-04 | 2008-04-30 | Compuestos triciclicos como inhibidores de metaloproteinasas matriciales |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100227859A1 (enExample) |
| EP (1) | EP2144893A2 (enExample) |
| JP (1) | JP2010526106A (enExample) |
| AR (1) | AR066412A1 (enExample) |
| CA (1) | CA2685389A1 (enExample) |
| CL (1) | CL2008001257A1 (enExample) |
| MX (1) | MX2009011749A (enExample) |
| PA (1) | PA8779101A1 (enExample) |
| PE (1) | PE20090223A1 (enExample) |
| TW (1) | TW200900397A (enExample) |
| WO (1) | WO2008137816A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE517106T1 (de) * | 2006-02-22 | 2011-08-15 | Vertex Pharma | Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren |
| WO2010091185A2 (en) * | 2009-02-05 | 2010-08-12 | Trustees Of Boston College | Inhibitors of fructose 1,6-bisphosphatase and methods of use thereof |
| CN102695704A (zh) * | 2009-04-06 | 2012-09-26 | Ptc医疗公司 | 吲哚衍生物及用于抗病毒治疗的方法 |
| WO2014123032A1 (ja) | 2013-02-08 | 2014-08-14 | 三菱瓦斯化学株式会社 | レジスト組成物、レジストパターン形成方法及びそれに用いるポリフェノール誘導体 |
| JP6401773B2 (ja) | 2013-03-11 | 2018-10-10 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Ｂｅｔブロモドメイン阻害剤およびこれを用いる治療方法 |
| EP2907512A1 (en) | 2014-02-14 | 2015-08-19 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Inhibitors of MMP-12 as antiviral Agents |
| JP7026439B2 (ja) | 2014-12-25 | 2022-02-28 | 三菱瓦斯化学株式会社 | 化合物、樹脂、リソグラフィー用下層膜形成材料、リソグラフィー用下層膜、パターン形成方法及び精製方法 |
| CN107428717B (zh) | 2015-03-31 | 2021-04-23 | 三菱瓦斯化学株式会社 | 抗蚀剂组合物、抗蚀图案形成方法、及用于其的多酚化合物 |
| JP6845991B2 (ja) * | 2015-03-31 | 2021-03-24 | 三菱瓦斯化学株式会社 | 化合物、レジスト組成物及びそれを用いるレジストパターン形成方法 |
| EP3346334B1 (en) | 2015-08-31 | 2020-08-12 | Mitsubishi Gas Chemical Company, Inc. | Use of a composition for forming a photoresist underlayer film for lithography, photoresist underlayer film for lithography and method for producing same, and resist pattern forming method |
| JP6919838B2 (ja) | 2015-08-31 | 2021-08-18 | 三菱瓦斯化学株式会社 | リソグラフィー用下層膜形成材料、リソグラフィー用下層膜形成用組成物、リソグラフィー用下層膜及びその製造方法、パターン形成方法、樹脂、並びに精製方法 |
| JP6848869B2 (ja) | 2015-09-10 | 2021-03-24 | 三菱瓦斯化学株式会社 | 化合物、樹脂、レジスト組成物又は感放射線性組成物、レジストパターン形成方法、アモルファス膜の製造方法、リソグラフィー用下層膜形成材料、リソグラフィー用下層膜形成用組成物、回路パターンの形成方法、及び、精製方法 |
| US10042251B2 (en) | 2016-09-30 | 2018-08-07 | Rohm And Haas Electronic Materials Llc | Zwitterionic photo-destroyable quenchers |
| GB201617339D0 (en) | 2016-10-12 | 2016-11-23 | Lytix Biopharma As | Therapeutic compounds |
| KR102435507B1 (ko) * | 2019-07-31 | 2022-08-24 | 일동제약(주) | 신규 벤조퓨란 유도체 및 이의 용도 |
| CN113929645B (zh) * | 2021-12-15 | 2022-03-11 | 长沙普济生物科技股份有限公司 | 一种光催化合成苯并呋喃基氨基酸表面活性剂的方法 |
| CN117045635A (zh) * | 2022-05-13 | 2023-11-14 | 中国海洋大学 | 一种3-苯基二苯并呋喃类化合物在药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998009957A1 (en) * | 1996-09-04 | 1998-03-12 | Warner-Lambert Company | Compounds for and a method of inhibiting matrix metalloproteinases |
| WO1998009934A1 (en) * | 1996-09-04 | 1998-03-12 | Warner-Lambert Company | Matrix metalloproteinase inhibitors and their therapeutic uses |
| TR200202164T2 (tr) * | 1999-08-18 | 2002-11-21 | Warner-Lambert Company | Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri. |
| MXPA01013172A (es) * | 2001-02-14 | 2002-08-21 | Warner Lambert Co | Inhibidores sulfonamida de metaloproteinasa de matriz. |
| US20030157110A1 (en) * | 2002-01-07 | 2003-08-21 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of metabolic disorders, including obesity and diabetes |
| JP2010507674A (ja) * | 2006-10-27 | 2010-03-11 | ワイス エルエルシー | マトリクスメタロプロテアーゼ阻害剤としての三環式化合物 |
-
2008
- 2008-04-30 PA PA20088779101A patent/PA8779101A1/es unknown
- 2008-04-30 PE PE2008000773A patent/PE20090223A1/es not_active Application Discontinuation
- 2008-04-30 AR ARP080101855A patent/AR066412A1/es unknown
- 2008-04-30 CL CL200801257A patent/CL2008001257A1/es unknown
- 2008-05-05 EP EP08755041A patent/EP2144893A2/en not_active Withdrawn
- 2008-05-05 MX MX2009011749A patent/MX2009011749A/es not_active Application Discontinuation
- 2008-05-05 JP JP2010506709A patent/JP2010526106A/ja not_active Withdrawn
- 2008-05-05 WO PCT/US2008/062593 patent/WO2008137816A2/en not_active Ceased
- 2008-05-05 US US12/598,868 patent/US20100227859A1/en not_active Abandoned
- 2008-05-05 TW TW097116522A patent/TW200900397A/zh unknown
- 2008-05-05 CA CA002685389A patent/CA2685389A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2009011749A (es) | 2009-11-11 |
| WO2008137816A3 (en) | 2009-05-14 |
| US20100227859A1 (en) | 2010-09-09 |
| EP2144893A2 (en) | 2010-01-20 |
| WO2008137816A2 (en) | 2008-11-13 |
| TW200900397A (en) | 2009-01-01 |
| WO2008137816A8 (en) | 2010-01-28 |
| AR066412A1 (es) | 2009-08-19 |
| CL2008001257A1 (es) | 2008-07-04 |
| CA2685389A1 (en) | 2008-11-13 |
| PA8779101A1 (es) | 2008-12-18 |
| JP2010526106A (ja) | 2010-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090223A1 (es) | Compuestos triciclicos como inhibidores de metaloproteinasas matriciales | |
| PE20120494A1 (es) | {5-[4-(3,3-DIMETIL-AZETIDINA-1-CARBONIL)-FENIL]-[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-2-IL}-AMIDA DE ACIDO CICLOPROPANOCARBOXILICO COMO INHIBIDOR DE LAS QUINASAS JANUS | |
| CL2012000059A1 (es) | Compuestos derivados de pirazolo[1,5-a]pirimidina; proceso de preparacion; composicion farmaceutica que los comprende; y su uso como inhbidores de trk-quinasa para el tratamiento de enfermedades o trastornos tales como dolor, cancer, inflamacion; entre otras. | |
| DOP2006000169A (es) | Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| DOP2007000051A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes | |
| EA200900924A1 (ru) | Циклизованные производные как ингибиторы eg-5 | |
| UY33694A (es) | ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?. | |
| UA109667C2 (xx) | Похідні хіназолін-4(3h)-ону, що використовуються як інгібітори pi3-кінази | |
| PE20090552A1 (es) | Compuestos de pirimidina hidrazida como inhibidores de pgds | |
| EA201100750A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
| HN2011001256A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratmiento o prevencion de diabetes | |
| BRPI0707493B8 (pt) | composto inibidor de enzimas e1 ativadoras e composição farmacêutica contendo o referido composto | |
| BRPI0818893B8 (pt) | compostos de tropano, suas composições farmacêuticas, seus usos e método in vitro de inibição de hsp90 em uma célula | |
| CL2011001967A1 (es) | Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico. | |
| EA201201663A1 (ru) | Производные 2-(ариламино)-3н-имидазо[4,5-b]пиридин-6-карбоксамида и их применение в качестве ингибиторов mpges-1 | |
| ECSP10010556A (es) | Piridinas y pirazinas como inhibidores de pi3k | |
| MY199552A (en) | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preapring the same | |
| DOP2013000105A (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis | |
| EA201070988A1 (ru) | Противовирусные терапевтические средства | |
| UY33245A (es) | Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas | |
| EA201591804A1 (ru) | Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы | |
| EA201070966A1 (ru) | Фолаты, композиции и применение указанных композиций | |
| EA201690129A1 (ru) | Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента | |
| EP2588491A4 (en) | NEW PEPTIDE AND ITS USE | |
| BRPI0511433A (pt) | derivados de quinolina substituìda como inibidores de cinesina mitótica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FX | Voluntary withdrawal |